ProCE Banner Activity

Immune Checkpoint Inhibitors for Advanced Gastroesophageal Cancers: Key Findings From ASCO GI 2019

Clinical Thought
Gain expert insight on the use of ICIs either as monotherapy or in combination with targeted agents when managing patients with gastric or GEJ cancer, as informed by recent data from the 2019 Gastrointestinal Cancers Symposium.

Released: February 26, 2019

Expiration: February 25, 2020

Share

Faculty

Steven Maron

Steven Maron, MD

Assistant Attending Physician
Gastrointestinal Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Steven Maron, MD

Assistant Attending Physician
Gastrointestinal Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Steven Maron, MD, has disclosed that he has received funds for research support from Roche/Genentech.